Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

Not yet recruiting · NCT07340619 · Registry updated 2026-08-03

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.	Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm	Not yet recruiting	Phase 2	2026-08-03		NCT07340619

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Pfizer	431
UNICANCER	111

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Centre Antoine Lacassagne	Nice	France	60
Centre Eugene Marquis	Rennes	France	11
Centre Leon Berard	Lyon	France	34
Institut Bergonie	Bordeaux	France	26
Institut Curie	Paris	France	44
Institut de Cancerologie de L'Ouest	Saint-Herblain	France	7
Institut Paoli Calmettes	Marseille	France	49
Oncopole Claudius Regaud	Toulouse	France	1